Stage IV non small-cell lung cancer research hub
4 indexed studies · 1 currently recruiting
- ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer (KEYVIBE-003)
This study is looking at a new combination medicine, MK-7684A, compared to an existing treatment, Keytruda, for advanced lung cancer. It aims to see if the new combination can help people live longer when their cancer has a specific marker called PD-L1.
Romania · Hungary - active not recruiting
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
This study looks at blood samples from people with advanced lung cancer or melanoma to help develop a tool. This tool aims to predict how well cancer treatments might work for individuals, helping doctors choose the best options.
United States · Germany · Israel - recruitingPHASE2
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
This study looks at a drug called crizotinib for advanced lung cancer where specific gene changes (ROS1 or MET) are found. It aims to see how well the drug works in these patients.
Canada - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)
This study looks at new drug combinations, including KEYTRUDA, for people with advanced lung cancer. Researchers want to see how well these combinations shrink cancer (response rate) and whether they are safe.
Italy · Spain · Poland